Videos
A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
Angeles Alvarez Secord, MD, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib, rucaparib, and niraparib.
Eugene B. Cone, MD, discusses the strategies for treating patients with prostate cancer who develop adverse events, such as cardiac events and immune-related events.
A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
A 75-Year-Old Man With Metastatic Castrate-Resistant Prostate Cancer
Ruben Mesa, MD, discusses the role of ruxolitinib and fedratinib, first-generation JAK inhibitors, as treatment of patients with myelofibrosis.
Bradley McGregor, MD, discusses a trial investigating atezolizumab and bevacizumab in patients with metastatic renal cell carcinoma and variant histologies and/or sarcomatoid features.
Lung Cancer
Julie R. Brahmer, MD, discusses the circumstances in which a physician can choose osimertinib over other EGFR tyrosine kinase inhibitors for patients with <em>EGFR</em>-mutant lung cancer.
